Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 7:10 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1969–1992 of 13,800 matching trials from the live ClinicalTrials.gov search.
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
LEO Pharma
Industry
Eligibility
Up to 16 Years
Enrollment
8,071 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
198
States / cities
Alabaster, Alabama • Anniston, Alabama • Birmingham, Alabama + 155 more
Conditions
Nephrotic Syndrome, Hyperlipidemia
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 17 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 1999
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Trauma
Interventions
Thromboelastometry guided transfusion
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
14 Years to 100 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Growth Hormone Deficiency, Pediatric, hGH (Human Growth Hormone), Endocrine System Diseases, Hormones, Pituitary Diseases
Interventions
Once weekly subcutaneous injection of TransCon hGH, Once daily subcutaneous injection of Genotropin
Drug
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Industry
Eligibility
3 Years to 12 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 13 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
rosiglitazone, inhaled human insulin, metformin, glimepiride
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
103
States / cities
Hueytown, Alabama • Ozark, Alabama • Tuscaloosa, Alabama + 95 more
Conditions
Coronary Artery Disease
Interventions
Coronary artery bypass grafting, Percutaneous coronary intervention
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
18
States / cities
Glendale, California • Atlanta, Georgia • Carmel, Indiana + 12 more
Conditions
Peripheral Vascular Diseases
Interventions
Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device.
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
53
States / cities
Jonesboro, Arkansas • Los Angeles, California • Sacramento, California + 42 more
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 1356, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
24
States / cities
Phoenix, Arizona • Chula Vista, California • Riverside, California + 20 more
Conditions
Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Interventions
Patritumab deruxtecan, Trastuzumab deruxtecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle

NCT02547441
Conditions
Rosacea
Interventions
CLS001 (Omiganan), Vehicle
Drug
Lead sponsor
Maruho Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
13
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 10 more
Completed Not applicable Interventional

Promoting Activity in Cancer Survivors

NCT03060941
Conditions
Physical Activity, Breast Cancer
Interventions
Physical activity education, Facility access, Supervised exercise sessions, Self-monitoring (Fitbit), Active living counseling
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Enrolling by invitation Not applicable Interventional

Pivotal Trial of the Boomerang Catheter for pDVA

NCT06311773
Conditions
Chronic Limb-Threatening Ischemia
Interventions
Boomerang Catheter
Device
Lead sponsor
Aveera Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
25
States / cities
San Bernardino, California • Sylmar, California • Torrance, California + 21 more
Conditions
Burns
Interventions
Enteral Glutamine, Placebo
Dietary Supplement
Lead sponsor
Daren K. Heyland
Other
Eligibility
18 Years and older
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
27
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 24 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

AuraClens™ System in Processing of Lipoaspirate for Autologous Fat Grafting to the Breast

NCT05258305
Conditions
Breast Fat Grafting Retention
Interventions
AuraGen 1-2-3 with AuraClens
Device
Lead sponsor
Tiger Biosciences, LLC.
Industry
Eligibility
22 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
14
States / cities
Scottsdale, Arizona • Beverly Hills, California • Miami, Florida + 10 more
Conditions
Cancer, Solid Tumors
Interventions
Vevorisertib, Fulvestrant, Paclitaxel
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Las Vegas, Nevada • Oklahoma City, Oklahoma • Charleston, South Carolina + 3 more
Conditions
Pulmonary Arterial Hypertension
Interventions
Notapplicable
Other
Lead sponsor
Actelion
Industry
Eligibility
Not listed
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
105
States / cities
Phoenix, Arizona • La Jolla, California • Loma Linda, California + 89 more
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
SPN-810, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
38
States / cities
Culver City, California • Orange, California • Colorado Springs, Colorado + 33 more
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
44
States / cities
Homewood, Alabama • Sun City, Arizona • La Jolla, California + 39 more
Conditions
Alzheimer's Disease
Interventions
Elenbecestat, Placebo
Drug
Lead sponsor
Eisai Co., Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
2,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
88
States / cities
Chandler, Arizona • Colton, California • Costa Mesa, California + 68 more
Conditions
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
Interventions
Famotidine, Celecoxib, Placebo
Drug
Lead sponsor
Leidos Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
Conditions
Advanced or Metastatic Solid Tumors
Interventions
ERAS-601, Cetuximab, Pembrolizumab
Drug
Lead sponsor
Erasca, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Sarasota, Florida • Boston, Massachusetts + 9 more
Conditions
Medical Oncology
Interventions
Anetumab ravtansine (BAY94-9343), Itraconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Santa Monica, California • Detroit, Michigan • St Louis, Missouri + 2 more
Conditions
Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions
Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
19 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
11
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more
Conditions
Atherosclerosis
Interventions
Canakinumab, Placebo, Standard of care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
315
States / cities
Athens, Alabama • Birmingham, Alabama • Fairhope, Alabama + 248 more